This observation prompted us to investigate the relationship between TET2 mutation status and occurrence of multiple hematologic malignancies, specifically through assessing effects of TET2 mutation status on probability of concomitant hematologic neoplasm-free survival in AITL patients. This evidence concerns the gene TET2 and hematopoietic and lymphoid system neoplasm.